Brenig Therapeutics Inc.

About Brenig Therapeutics Inc.

Brenig Therapeutics is a biotechnology company focused on pioneering innovative small-molecule therapies for neurodegenerative diseases. Leveraging AI and machine learning, along with decades of drug development expertise, they aim to deliver disease-modifying treatments targeting the root causes of debilitating neurological conditions, starting with Parkinson's disease.

Products & Services

BT-267:A selective, brain-penetrant small-molecule inhibitor of LRRK2, designed for Parkinson's disease. It offers high brain penetration, minimal peripheral exposure, and a favorable safety profile, aiming to slow or halt disease progression by targeting lysosomal and mitochondrial dysfunction.

BT-409:A CNS-penetrant small-molecule inhibitor of the NLRP3 inflammasome for Parkinson's disease and potentially other neuroinflammatory conditions like multiple sclerosis, Alzheimer's, and stroke. It shows a promising safety and pharmacokinetic profile, with Phase 1 studies planned for 2025.

Specialties

Neurodegenerative disease therapies AI-driven drug discovery Small-molecule inhibitors Parkinson's disease treatment Neuroinflammation treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 65000000 MR: - FA: $65 million FAN: 65000000	D: 2024-07-23 FD: 2024-07-23	5 investors

Series A Latest

2024-07-23

$65.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David L. Lucchino

CEO

T

Tien Dam

Chief Medical Officer

Recent News